Maintenance therapy for HER2-positive advanced breast cancer
Treatments studied
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is HER2-positive and has spread to other parts of the body or cannot be removed with surgery.
- You have not had chemotherapy for advanced breast cancer, though you may have had hormone therapy for it.
- If you had chemotherapy or other treatments for earlier-stage breast cancer, it must have been more than 12 months ago.
- You are in good overall health, with no serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of three drugs (pyrotinib, trastuzumab, and pertuzumab) as ongoing treatment after initial chemotherapy for HER2-positive advanced breast cancer that has not gotten worse. It aims to see if this maintenance therapy can help keep the cancer under control.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.